Chromogranin A (CgA) in Pheochromocytoma and in Multiple Endocrine Neoplasia Type 1.

#1027

Introduction: Chromogranin A (CgA) as a main, nonspecific marker of neuroendocrine tumors (NET) has been applied for diagnostic purposes and for monitoring the treatment of NET. Pheochromocytoma and MEN-1 syndrome represent rare neuroendocrine tumours.

Aim(s): The aim of the study was to evaluate the usefulness of CgA measurements in patients with pheochromocytoma and multiple endocrine neoplasia type 1.

Materials and methods: 20 patients with pheochromocytoma and 12 patients with MEN-1 syndrome. Chromogranin A was measured by immunoradiometric method (CIS bio, France).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Glinicki P, Jeske W, Bednarek-Papierska L, Rosłonowska E, Zgliczyński W,

Keywords: chromogranin A, CgA, pheochromocytoma, multiple endocrine neoplasia, neuroendocrine tumors,